Method for controlling obesity using minimally invasive means
OwnerMubin I. Syedinventor
Life of this patent
Estimating the term…
Abstract
Methods for controlling obesity using minimally-invasive procedures including introducing embolic crystal particles that are naturally occurring and mostly non-toxic salts into the arterial capillaries feeding the sections of the stomach where the appetite inducing hormone, ghrelin, is produced to limit the blood flow to the region reducing appetite; introducing a virus vector or antisense oligonucleotide to inhibit the production of ghrelin and reduce the appetite; and introducing a soluble embolic particle with a virus vector or antisense oligonucleotide which will inhibit the flow of blood initially and then dissolve and release the inhibit vector to the region, generating ghrelin to control the appetite.
Claims19
A method of treating an obese patient comprising:
- delivering modified virus vectors configured to target ghrelin producing cells to inhibit ghrelin production, wherein the modified virus vectors are embedded within dissolvable embolic particles that dissolve over time in human blood, to targeted ghrelin production sites,
- wherein a size of the dissolvable embolic particles, made from a solution of one or a mixture of salts selected from magnesium phosphate, calcium di-hydrogen phosphate, potassium di-hydrogen phosphate, that dissolve over time in blood, is between 300 and 500 microns.
A method of treating an obese patient, the method comprising:
- embedding modified virus vectors that inhibit ghrelin production in dissolvable embolic particles made from, one of, or a mixture of, magnesium phosphate, calcium di-hydrogen phosphate, or potassium di-hydrogen phosphate, wherein a PH value of the embolic particles is adjusted for minimally invasive non-toxic application in the obese human patient by addition of magnesium hydroxide or potassium hydrogen phosphate to the solution from which the embolic particles are made;
- delivering the embolic particles with the embedded modified virus vectors to the ghrelin production sites in the obese human patient using a percutaneously introduced catheter;
- wherein the modified virus vectors are delivered to targeted ghrelin production sites using the embolic particles that release the modified virus vectors as the embolic particles dissolve in blood over time.
The method of claim, 17, wherein the imaging technique is selected from the group consisting of x-ray fluorescence or ultrasound tracking.
A method of treating an obese patient, the method comprising:
- delivering modified virus vectors, that act to inhibit a production of ghrelin by the cells that produce ghrelin in a human body, contained within dissolvable embolic particles that dissolve over time in human blood, to targeted ghrelin production sites,
- wherein the dissolvable embolic particles are made from, one of, or a mixture of, magnesium phosphate, calcium di-hydrogen phosphate, or potassium di-hydrogen phosphate, and
- wherein a PH value of the dissolvable embolic particles is adjusted using magnesium hydroxide or calcium hydroxide.
Dependencies are inferred from the claim text.